CVS unveils changes to 2018 formulary

CVS Health Corp. (NYSE:CVS) will remove Gaucher's disease drug Elelyso taliglucerase alfa and diabetes drug Jardiance empagliflozin from its 2018 Standard Control Formulary.

Elelyso from Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX) is a plant cell-expressed recombinant form of human glucocerebrosidase (GCase). Jardiance is a sodium-glucose cotransporter 2 (SGLT2) inhibitor from Boehringer Ingelheim GmbH (Ingelheim, Germany) and Eli Lilly and Co. (NYSE:LLY). The PBM instead granted SGLT2 inhibitor Invokana canagliflozin from Johnson & Johnson (NYSE:JNJ) preferred status...